Neurology 1305 - Neurology Alert - May 01, 2009

Target Audience:

This activity is intended for the neurologist.

Accreditation:

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

AHC Media designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty

Physician Editor
Matthew Fink, MD
Vice Chairman, Professor of Clinical Neurology
Weill Medical College
Chief of Division of Stroke and Critical Care Neurology
NewYork Presbyterian Hospital

Peer Reviewer
M. Flint Beal, MD
Professor and Chairman,
Department of Neurology and Neuroscience

Assistant Editors
Norman Relkin, MD, PhD
Director, Memory Disorders Program
Associate Professor of Clinical Neurology
Weill Cornell Medical College

Dara G. Jamieson, MD
Associate Professor of Clinical Neurology
Weill Cornell Medical College

Michael Rubin, MD
Professor of Clinical Neurology
Weill Cornell Medical College

Alan Z. Segal, MD
Associate Professor of Clinical Neurology;
Specialty area, Stroke and Critical Care

Padmaja Kandula, MD
Assistant Professor of Neurology;
Specialty area, Epilepsy

Subjects:

  • Quinacrine Fails to Stop Prion Disease
  • Pregnancy in Women with Migraine: A Time of Increased Vascular Risk
  • CADASIL: Variable Genetics Predict Unique Presentations
  • Inclusion Body Myositis: A Final Word
  • Long-term EEG Monitoring: 'Holter' Monitor for the Brain

Objectives:

  • Present current scientific data regarding diagnosis and treatment of neurologic disease, including stroke, Alzheimer?s disease, transient ischemic attack, and coma
  • Discuss the pathogenesis and treatment of pain
  • Present basic science lessons in brain function
  • Discuss information regarding new drugs for commonly diagnosed diseases and new uses for traditional drugs
  • Discuss nonclinical issues of importance to neurologists, such as the right to die and the physician?s legal obligation to patients with terminal illness

Financial Disclosure:

Neurology Alert's physician editor, Matthew Fink, MD, reports no consultant, stockholder, speaker's bureau, research, or other relationships related to this field of study. Peer reviewer M. Flint Beal, MD, reports no consultant, stockholder, speaker's bureau, research, or other financial relationship with any company having ties to this field of study. Author Norman Relkin, MD, PhD reports that he receives grant/research support from Baxter Bioscience, and is a consultant to Eisai, Pfizer, Myriad, and Smart Genetics. Dr. Relkin also reports he is leading a Phase 3 clinical trial of Intravenous Immunoglobulin for treatment for Alzheimer's disease, funded by the National Institute on Aging and Baxter Healthcare. Assistant editor Dara G. Jamieson, MD reports she is a retained consultant for Boehringer Ingelheim, Merck, and Ortho-McNeil, and is on the speaker's bureau for Boehringer Ingelheim and Merck. Assistant editors Alan Z. Segal, MD and Padmaja Kandula, MD report no financial relationships relevant to this field of study. Assistant editor Michael Rubin, MD, FRCP(C) reports that he receives grant/research support from Pfizer and is on the speaker's bureau of Athena Diagnostics.

Copyright 2009 AHC Media. All rights reserved.